Compare SENEA & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SENEA | TBPH |
|---|---|---|
| Founded | 1949 | 2013 |
| Country | United States | United States |
| Employees | 6895 | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 908.7M | 824.9M |
| IPO Year | N/A | 2013 |
| Metric | SENEA | TBPH |
|---|---|---|
| Price | $141.90 | $16.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.40 |
| AVG Volume (30 Days) | 77.8K | ★ 288.8K |
| Earning Date | 06-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | N/A | $8.46 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.21 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $87.99 | $9.10 |
| 52 Week High | $167.52 | $21.03 |
| Indicator | SENEA | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 44.36 | 49.08 |
| Support Level | $131.44 | $16.14 |
| Resistance Level | $148.36 | $17.21 |
| Average True Range (ATR) | 5.67 | 0.38 |
| MACD | 0.25 | -0.06 |
| Stochastic Oscillator | 22.62 | 39.66 |
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.